Latest News

MiMedx Group recently published new peer-reviewed data in the Journal of Inflammation showing that its Purion-processed DHACM and LHACM placental allografts exert multifactorial immunomodulatory effects on key inflammatory cells involved in wound healing. The findings that these allografts both temper inflammatory monocyte and macrophage activity and enhance pro-reparative functions such as efferocytosis and cell survival could strengthen the medical community’s confidence in MiMedx’s...

PAR Technology (PAR) is back in the spotlight after Wasatch Global Investors exited its position, citing weaker than expected organic growth, just as the company leans on new products like Smart Passes to reset its story. See our latest analysis for PAR Technology. That backdrop helps explain why, even with a recent 1 month share price return of about 8 percent and a 1 day gain of nearly 3 percent to 36.83 dollars, PAR’s year to date share price return is still deep in the red. Its 1 year...

Suzuki Motor (TSE:7269) shares have quietly pushed higher over the past month, and that steady climb has investors asking whether this auto and motorcycle maker still offers reasonable upside from here. See our latest analysis for Suzuki Motor. That recent climb sits on top of a strong run, with a roughly mid 20s year to date share price return and an impressive triple digit multi year total shareholder return, suggesting momentum is still firmly on Suzuki Motor's side. If Suzuki's move has...

Anywhere Real Estate (HOUS) is back on investors radar after a series of upbeat calls from Keefe, Bruyette & Woods, Barclays, and JP Morgan, signaling improving confidence in its residential brokerage and franchise operations. See our latest analysis for Anywhere Real Estate. Those upbeat calls land at a time when momentum is clearly building, with Anywhere Real Estate’s share price up sharply over the past quarter and its year to date share price return far outpacing its already impressive 1...

Token (TSE:1766) just rolled out a sizeable share buyback, with board approval to retire a meaningful slice of its outstanding stock. This move immediately sharpens the conversation around valuation and capital allocation. See our latest analysis for Token. The buyback news lands after a steady climb, with the share price up strongly year to date and a robust three year total shareholder return suggesting momentum is still in Token’s favor. If this kind of capital return story has your...

OceanaGold (TSX:OGC) just cleared a major hurdle in New Zealand, securing final government approval for its Waihi North Project and the Wharekirauponga Underground mine, a long dated but meaningful growth driver. See our latest analysis for OceanaGold. The latest approval lands after a string of positive catalysts, including progress on the Brewer copper gold earn in in the US. This helps explain why the stock’s 30 day share price return of 14.25 percent sits within a much larger 1 year total...

Aya Gold & Silver (TSX:AYA) is back on traders radars after filing fresh technical reports that extend Zgounder s mine life to 2036 and outline new economics for the Boumadine project in Morocco. See our latest analysis for Aya Gold & Silver. That backdrop of longer mine life and fresh drill results helps explain why Aya s 1 month share price return is 35.66 percent and its year to date share price return sits at 71.42 percent, with a 1 year total shareholder return of 77.58 percent,...

GoDaddy (GDDY) has quietly slipped this year, with the stock down around 36% year to date despite solid revenue and earnings growth, and that disconnect is exactly what has investors rechecking their assumptions. See our latest analysis for GoDaddy. Despite the drop, the 1 day and 7 day share price returns have turned positive, and that small change in tone sits against a still healthy three year total shareholder return of nearly 70%. This suggests long term holders have been well rewarded...

If you have been wondering whether KBR is a beaten down opportunity or a value trap, you are not alone. This article is going to walk through the numbers with you. After sliding to around $42.80, the stock is down 1.6% over the last week and up 5.7% over 30 days, but still sitting on a heavy year-to-date loss of 26.1% and a 23.9% drop over the past year, despite being up 51.8% over five years. That kind of whiplash performance has come alongside a steady stream of contract wins and strategic...

In recent coverage, Mizuho and Citi both initiated positive ratings on Spyre Therapeutics, highlighting its half-life extended monoclonal antibody pipeline for inflammatory bowel and other autoimmune diseases. Analysts emphasized Spyre’s ability to explore novel antibody combinations and its rheumatic disease program, with several firms now expressing broad confidence in the company’s development approach. We’ll now explore how this wave of optimistic analyst coverage, particularly around...

Expand Energy (EXE) just released a standout earnings update, with adjusted EPS jumping sharply year over year on stronger oil, gas, and NGL sales, plus sizable contributions from marketing and derivatives. See our latest analysis for Expand Energy. Even after this blowout quarter, the stock has cooled off recently, with a 30 day share price return of minus 8.1 percent. However, a 1 year total shareholder return of 17.2 percent still signals that momentum is building over the longer run. If...

HeartFlow (HTFL) has climbed about 9% in a day and 8% over the past week, an eye catching move for a relatively young medtech stock. Investors are asking whether this momentum is sustainable. See our latest analysis for HeartFlow. The latest surge comes after a choppy few months, with a 30 day share price return of 5.21% but a 90 day share price return still in negative territory, suggesting momentum is only just starting to rebuild. If HeartFlow's recent move has your attention, it could be...

Trevi Therapeutics (TRVI) just named veteran finance executive David Hastings as its next Chief Financial Officer, effective January 6, 2026, a move that immediately sharpened investor focus on the stock’s trajectory. See our latest analysis for Trevi Therapeutics. The timing of Hastings’ appointment coincides with Trevi’s 90-day share price return of nearly 50 percent and roughly 180 percent year-to-date share price gain, which together indicate firmly building momentum, supported by a...

Equinox Gold (TSX:EQX) has quietly turned into one of the better performing gold names this year, with the stock up roughly 48% year to date and more than doubling over the past year. See our latest analysis for Equinox Gold. The recent pullback, including a 6.2% seven day share price return decline, looks more like a breather after a powerful run. Year to date share price gains and a three year total shareholder return both point to strong, still building momentum around Equinox Gold’s...

Chimera Investment Corporation’s board declared a fourth-quarter cash dividend of US$0.37 per common share, payable on January 30, 2026, to shareholders of record as of the December 31, 2025 ex-dividend date. This dividend decision sheds light on Chimera’s ongoing approach to distributing income from its diversified mortgage asset portfolio, a key focus for income-oriented investors. We’ll now explore how this latest dividend declaration shapes Chimera Investment’s broader investment...

Earlier this week, Sphere Entertainment announced that veteran entertainment technologist Felicia Yue has joined as Executive Vice President and Chief Technology Officer, where she will oversee the advanced display, playback, interactive, and audio systems underpinning the company’s immersive Sphere venues and Sphere Studios. Her track record building widely used broadcast technologies like the NFL’s yellow 1st‑down line and CNN’s election “Magic Wall” underscores Sphere’s push to deepen its...

In mid-December 2025, Takeda reported positive topline data from two pivotal Phase 3 trials of its next‑generation oral TYK2 inhibitor zasocitinib in adults with moderate‑to‑severe plaque psoriasis, showing superiority to placebo and an active comparator on key skin‑clearance endpoints. Because zasocitinib is a once‑daily oral pill that achieved high rates of near‑complete and complete skin clearance, it could reshape treatment options in plaque psoriasis if successfully approved. We’ll now...

ANI Pharmaceuticals (ANIP) has quietly kept its momentum, with shares edging higher over the past week and delivering strong gains this year. That strength invites a closer look at what is driving the move. See our latest analysis for ANI Pharmaceuticals. With the share price now at $82.83, the recent 7 day share price return of just over 3 percent sits against a much stronger year to date share price return and a standout multi year total shareholder return record. This suggests positive...

ITOCHU has now completed its previously announced share buyback program, repurchasing a total of 18,371,700 shares, or 1.3%, for ¥149,999.98 million by December 16, 2025. This sizable capital return reduces the share count and may strengthen perceptions of management confidence and commitment to long-term shareholder value. We’ll now examine how the completion of this ¥149,999.98 million buyback could influence ITOCHU’s investment narrative and capital allocation outlook. These 16 companies...

As the U.S. stock market experiences a resurgence, with major indices like the Nasdaq and S&P 500 seeing notable gains driven by tech shares, investors are keenly observing opportunities that may arise from these fluctuations. In such an environment, identifying undervalued stocks can be crucial for those looking to capitalize on potential growth while maintaining a balanced portfolio amidst shifting market dynamics.

As the U.S. stock market experiences a surge, particularly in tech shares, investors are closely monitoring growth companies with high insider ownership as potential opportunities amidst this renewed risk appetite. In such an environment, stocks that combine robust earnings growth with significant insider stakes can offer insights into management confidence and alignment with shareholder interests.

Major stock indexes in the United States have recently experienced a surge, driven by gains in technology shares and positive economic indicators. While the term "penny stocks" might seem outdated, it still refers to shares of smaller or newer companies that can offer significant potential for growth. By focusing on those with solid financial foundations, investors can uncover opportunities that may provide stability and upside potential.

As the U.S. market navigates a landscape marked by surging tech shares and volatile index movements, investors are keenly observing how these dynamics impact small-cap stocks, particularly within the S&P 600. With major indices like the Nasdaq and S&P 500 experiencing gains driven by AI-related optimism, identifying lesser-known stocks with strong fundamentals can be key to capitalizing on potential growth opportunities amidst broader market shifts.

As the U.S. stock market experiences a resurgence, with major indexes like the Nasdaq and S&P 500 seeing notable gains driven by tech shares, investors are keenly observing opportunities across various sectors. In this dynamic environment, dividend stocks stand out as a compelling option for those seeking consistent income streams alongside potential capital appreciation.